• Product mockup
  • Product mockup
  • Product mockup
1 3

The Sky Shop For Hope

White Monstera Pet Bandana

White Monstera Pet Bandana

$25.00 USD
$25.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Get ready to make a statement with this all-over print bandana. Mix up your outfits by using this as a headband, necktie, or armband. In fact, why not get a second bandana to match your pet? Grab a few and hit the streets in style!

• 65% recycled polyester, 35% polyester
• Fabric weight: 2.95 oz/yd² (100 g/m²)
• Breathable and moisture-wicking material
• Lightweight and soft to the touch
• Double-folded edges
• Single-sided print
• Multifunctional
• UPF50+ protection
• Fabric is OEKO-TEX 100 standard and Global Recycled Standard (GRS) certified
• Blank product components sourced from China

Important sizing information: the smallest bandana size is made for small pets and won’t fit a grown-up. Please choose the medium or large size if you’re ordering for a grown-up.

Size guide

  LENGTH (inches) WIDTH (inches)
S 17 ⅜ 17 ⅜
M 21 ¼ 21 ¼
L 25 ¼ 25 ¼
  LENGTH (cm) WIDTH (cm)
S 44 44
M 54 54
L 64 64
View full details

Recent News

View all
  • Phase 1/2 Trial Launches for Innovative Pancreatic Cancer Immunotherapy

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

  • FDA Approves NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Cancer

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

  • Immunotherapy for Pancreatic Ductal Adenocarcinoma: Barriers and Opportunities

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

1 3
View all